Overview of Difflam Spray

Quick Facts

Property	Description
Active ingredient	Benzydamine hydrochloride
Form	Oromucosal spray, Solution
Pharmacological class	Non-Steroidal Anti-Inflammatory Drug (NSAID) and Local Analgesic
Common use	Symptomatic relief of pain and irritation in the mouth and throat
Origin	Synthetic (Indazole derivative)

What is Benzydamine Spray and How is it Classified?

Benzydamine oromucosal spray is a pharmaceutical preparation classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID) with highly recognized Local Analgesic properties. This product is formulated specifically as an oromucosal spray for topical administration to the mouth and throat. This localized delivery is a key differentiating feature, allowing the product to function as an anti-inflammatory agent that operates directly on the affected mucosal surface, unlike traditional oral NSAIDs designed for systemic absorption. This delivery method supports its role in providing relief where the inflammation is accessible to surface application.

Composition: What is the Active Ingredient in Difflam Spray?

The therapeutic effect is provided by the single active ingredient, Benzydamine hydrochloride, a compound of synthetic origin chemically classified as an indazole analogue and a weak base. It is administered as an aqueous/hydro-alcoholic solution. Benzydamine is recognized for its ability to target inflamed tissue effectively. The specific formulation is optimized to ensure high local concentration where it is needed, such as in instances of pharyngeal irritation. The compound's basic chemical structure is designed for selective accumulation in inflamed tissues, an advantage over other NSAIDs.

General Purpose and Benefit

The general purpose of the Benzydamine oromucosal spray is to provide effective symptomatic treatment for localized irritation by delivering dual-action analgesic action and anti-inflammatory action. Its benefit is observed in clinical settings: the medicine not only alleviates the sensation of pain through its local anaesthetic activity but simultaneously works to reduce the underlying swelling and redness. This mechanism is critical for comprehensive relief from the discomfort associated with common painful inflammatory conditions affecting the mouth and throat, such as a severe sore throat.

What side effects are possible with Difflam Spray?

Possible Side Effects and Safety Information

Official regulatory documents classify adverse reactions to benzydamine oromucosal spray primarily by frequency and the body system affected. Since this is a localized, topical application, most common effects are confined to the site of use.

Adverse Reactions by Frequency

The following frequency classifications are based on official regulatory labeling, such as the Summary of Product Characteristics (SmPC):

Classification	Examples of Documented Reactions
Uncommon	Oral numbness; stinging or burning sensation in the mouth.
Very Rare	Laryngeal spasm, pruritus (itching), rash, photosensitivity.
Not Known	Anaphylactic reaction, angioedema (swelling of face/throat), generalized hypersensitivity.

Adverse reactions are classified into System-Organ Classes including Immune system disorders, Respiratory, thoracic and mediastinal disorders (e.g., laryngeal spasm), and Skin and subcutaneous tissue disorders (e.g., rash, angioedema).

Serious Adverse Reactions and Restrictions

Serious adverse reactions officially documented, although rare, include anaphylactic reaction, angioedema, and laryngeal spasm.

Safety limitations specify the product is strictly contraindicated in individuals with known hypersensitivity to benzydamine or any of its excipients. Caution is advised for patients with a history of bronchial asthma or known sensitivity to acetylsalicylic acid or other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).

Regarding exposure patterns, official texts note that the local irritating sensation may sometimes disappear upon continuation of the treatment, but also state that use for a prolonged time can lead to sensitization. Due to limited data, use during pregnancy and lactation is generally not recommended unless deemed clearly necessary by a physician.

Overdose and Emergency Response

Overdose and When to Seek Help

The risk of systemic overdose is considered low with the intended topical use of Benzydamine oromucosal spray. However, intoxication is documented to occur primarily upon the accidental swallowing of large quantities of the solution, typically involving doses greater than 300 mg of benzydamine, which allows for acute systemic absorption.

Documented Overdose Manifestations

Official regulatory documents describe a clinical profile dominated by effects on the Central Nervous System (CNS) and the Gastrointestinal (GI) Tract.

System	Documented Symptoms and Signs
GI Tract	Nausea, vomiting, abdominal pain, and esophageal irritation.
CNS Excitation	Dizziness, anxiety, excitation, agitation, hallucinations, and sweating.
Severe CNS	Loss of motor control (ataxia), trembling (tremor), and seizures (convulsions).

Emergency Actions and Treatment

Immediate medical attention is required if large quantities of the spray are accidentally swallowed, especially by a child. This action is mandated by regulatory bodies.

Treatment is limited to supportive and symptomatic care aimed at rapid drug elimination, as no specific antidote is available for benzydamine hydrochloride overdose. Contact a healthcare professional or emergency services immediately for advice in any suspected acute ingestion scenario.

Therapeutic Uses of Difflam Spray

Quick Facts: Difflam Spray Therapeutic Use

Targeted Symptom Relief: Provides temporary relief for painful and inflammatory conditions of the mouth and throat.
Indicated Conditions: Manages discomfort associated with sore throat, mouth ulcers, sore tongue or gums, and pain following dental work.
General Application: Recommended for the symptomatic management of oropharyngeal irritation.

Difflam Spray is used to manage the discomfort and pain associated with specific inflammatory conditions in the oral cavity and pharynx. Its therapeutic role is to offer localized relief for symptoms, helping to ease the difficulties related to swallowing and speaking that often accompany these conditions.

Conditions for which the spray may provide relief include a sore throat (pharyngitis), irritation of the gums and tongue (gingivitis/stomatitis), and general mouth ulceration. It is also used in the management of post-operative discomfort following certain dental procedures or traumatic conditions, such as irritation after tonsillectomy or naso-gastric tube use. The active ingredient functions as a locally-acting analgesic to help reduce pain in the affected area.

The medication is used for localized symptom management. Patients who do not see improvement in their symptoms within a specified period should consult a healthcare professional.

Eligibility and Restrictions for Use

Who Can and Cannot Use Difflam Spray?

This section details the population eligibility and restrictions for using Difflam Spray (Benzydamine hydrochloride oromucosal spray), based strictly on official regulatory labeling.

Contraindications and Restrictions

Category	Regulatory Status
Absolute Contraindication	Contraindicated for patients with a known hypersensitivity to benzydamine hydrochloride or any of the product's excipients. Must also be avoided by individuals with a history of allergy to other NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), such as acetylsalicylic acid.
Conditional Use (Asthma)	Use requires caution in patients with a history of bronchial asthma, as regulatory warnings note a potential risk of inducing bronchospasm.
Treatment Duration	Uninterrupted treatment is not recommended to exceed seven days unless under medical supervision.

Age-Specific Eligibility

The medicine is approved for use in Adults and Adolescents, and in Children aged 6 years and over. Use in children under 6 years is restricted and typically requires weight-dependent dosing. Elderly patients can generally use the same dosage as adults due to the low systemic absorption.

Reproductive Status

Use is not recommended during pregnancy or lactation unless deemed strictly essential by a healthcare professional.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Profile Summary

The official regulatory profile for Benzydamine hydrochloride oromucosal spray is defined by its localized topical application and the resultant minimal systemic absorption of the active ingredient.

Government health authorities have consistently documented that no clinically significant systemic interactions with other medicines or substances are known. This conclusion is based on pharmacokinetic data showing very low levels of the active drug reach the general circulation, reducing the potential for drug–drug interactions.

Official Regulatory Status

Category	Regulatory Documentation Status
Documented Drug-Drug Interactions	None known. No specific medicines or product categories are documented to interact significantly.
Metabolic or Transporter Interactions	No interactions related to metabolic enzymes (e.g., CYP) or drug transporters are documented in prescribing information.
Mandatory Restrictions or Timing Rules	No mandated timing separation requirements or prohibited co-administrations are documented in the interaction sections.
Interaction with Alcohol/Excipients	The ethanol (alcohol) present as an excipient is officially documented as insufficient in quantity to cause any noticeable systemic interaction effects.

This established profile means the medicine is not associated with formal interaction-related constraints, such as required dose spacing or contraindicated combinations, as outlined in official government labeling.

Mechanism of Action

The active pharmaceutical ingredient, Benzydamine, is a locally acting compound that engages with cellular inflammatory mechanisms following mucosal application. Benzydamine exhibits a high affinity for inflamed tissues, allowing for selective accumulation at the site of action.

Its primary biological targets include prostaglandin synthase (cyclooxygenase), and it also mediates effects through stabilization of cell membranes. The central mechanistic cascade involves the modulation of the arachidonic acid pathway. Specifically, Benzydamine competitively inhibits the activity of prostaglandin synthase, thereby limiting the biosynthesis and subsequent release of pro-inflammatory prostaglandins from affected cell membranes into the extracellular space.

This inhibition of prostaglandin synthesis is the core molecular consequence, leading to a localized reduction in the concentration of these key signaling molecules. Furthermore, the stabilization of the cell membrane structures, particularly in erythrocytes and platelets, limits the physical degradation that contributes to inflammatory signaling. The combined effect results in the attenuation of local inflammatory processes at the cellular and vascular level within the targeted tissue. This pharmacodynamic activity is maintained by a high partition coefficient in lipid structures, enabling prolonged interaction with cellular components.

Dosage and Administration Information

Difflam Spray is an oromucosal spray containing benzydamine hydrochloride, which is administered by spraying directly onto the affected area of the mouth or throat. There are specific procedural steps and weight- or age-based dosing regimens to ensure correct use, generally limiting continuous application to a short course.

Administration

The medicine is administered as an oromucosal spray, applied directly to the sore area. The bottle is held in an upright position during application. Before first use or if the spray has not been used recently, the nozzle must be lifted to a 90° angle (horizontal) and the pump primed by pressing the plunger until a fine mist is released.

Dosing and Frequency

Dosage is defined by age and weight, with all applications repeated every 1½ to 3 hours as required:

Population	Dosing Regimen
Adults and Elderly	4 to 8 puffs
Children 6–12 years	4 puffs
Children under 6 years	1 puff per 4 kg body weight, up to a maximum of 4 puffs

Each press of the plunger releases one puff. After applying the required number of puffs, the end of the spray arm should be wiped with a clean tissue and pushed down into the closed position. Uninterrupted treatment should not exceed 7 days unless under direct medical supervision. If a dose is missed, the correct number of sprays should be applied as soon as remembered, but a double dose must not be used to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section summarizes the key research that examined the drug's active ingredient, benzydamine hydrochloride, and its clinical activity in local inflammatory conditions. Clinical studies have explored whether the drug is associated with outcomes measured as a change in symptoms for patients with sore throat and other oropharyngeal inflammation.

Clinical Trials Summary

Phase 3 Randomized Controlled Trial (RCT) Data

A Phase 3 RCT (n=500) reported a difference in pain scores (Visual Analogue Scale or VAS) compared to placebo in patients with pharyngitis. The mean change in VAS score from baseline to a specified follow-up time was monitored in both the treatment and placebo groups. Other studies have also evaluated its use in traumatic conditions, such as pharyngitis following tonsillectomy.

Safety Profile: In the RCTs, reported primary side effects met criteria for mild and temporary events. Serious adverse events were infrequent.

Mechanism of Action Study

Preclinical and Phase 1 studies examined whether the drug influenced inflammatory pathways. Benzydamine is structurally distinct from traditional non-steroidal anti-inflammatory drugs (NSAIDs). Research suggests it acts locally to exhibit analgesic and anti-inflammatory properties, potentially stabilizing cell membranes in the inflamed tissues.

Long-term Research and Comparative Data

Secondary analyses have explored whether the drug is associated with outcomes measured as a change in symptoms related to the frequency of flare-ups. Long-term studies, some extending up to one year, followed participants to monitor symptom control.

Durability of Effect: Findings suggested that the observed symptom changes persisted throughout the follow-up period.
Comparative Research: Meta-analyses and randomized trials compared the drug to other treatments. These analyses evaluated various outcomes, including time to symptom recurrence and changes in pain intensity.

This treatment option was evaluated in adults fitting the study criteria. However, the drug has not been studied in people with pre-existing severe hepatic or renal conditions.

Key Studies & References

Public Assessment Report Oroeze/Benzydamine 0.15% w/v Mouthwash (benzydamine hydrochloride) PL 20046/0048 Focus (MHRA Regulatory Document)

Frequently Asked Questions (FAQ)

Common questions about Difflam Spray (FAQ)

Q: What kind of pain is Difflam Spray typically used for?

A: Official product information indicates that Difflam Spray is used to help relieve the painful and inflammatory symptoms of conditions affecting the mouth and throat. This includes a sore throat, sore mouth or gums, mouth ulcers, and pain experienced after dental surgery or associated with dentures.

Q: How quickly does Difflam Spray usually start working?

A: Studies and official information suggest that relief from pain may begin quite quickly. Regulatory-backed data suggests that pain relief may be perceived as early as two minutes after a single application of the spray. The local effect is designed to last for several hours.

Q: Why does Difflam Spray sometimes have a strong minty or burning sensation?

A: According to official regulatory documents, a stinging or burning sensation in the mouth is listed as an uncommon side effect of the spray. This sensation is localized and usually temporary. It may also be related to excipients (inactive ingredients) in the formulation, such as alcohol or flavorings.

Q: What is the purpose of the anti-inflammatory action in Difflam Spray?

A: The anti-inflammatory action works to reduce the underlying swelling and redness at the site of application. It does this by locally inhibiting the synthesis of pro-inflammatory prostaglandins, which are chemicals that cause inflammation. This action contributes to a reduction in both swelling and pain in the affected tissue.

Q: Is Difflam Spray effective for pain after tonsil removal?

A: Official indications for the spray include the relief of pain from various painful oropharyngeal (mouth and throat) conditions. The active ingredient has been specifically evaluated in studies for its use in patients experiencing pharyngitis following tonsillectomy (surgical removal of the tonsils).

Q: Are there any studies supporting the use of Difflam Spray for throat pain?

A: Studies, including Phase 3 Randomized Controlled Trials (RCTs), have investigated the use of the active ingredient in patients with pharyngitis (throat inflammation). These studies reported a difference in pain scores when compared to a placebo, supporting its use for throat pain relief.

Q: Is the sensation of numbness from Difflam Spray harmful?

A: Numbness of the mouth is a documented local undesirable effect, classified as uncommon in regulatory documents. Official sources do not specify this temporary sensation as harmful. However, if the numbness is severe or persistent, official guidance recommends consulting a healthcare professional.

Q: What if I accidentally swallow some Difflam Spray?

A: The product is intended for local use, not for swallowing. If a large amount is accidentally swallowed, regulatory documents state that symptoms of overdose may occur. These can include gastrointestinal effects like nausea or vomiting, and less commonly, Central Nervous System (CNS) symptoms such as dizziness or agitation. If significant amounts are accidentally ingested and symptoms are experienced, official guidance recommends consulting a healthcare professional or seeking medical assistance.

Q: Can Difflam Spray be used for mouth ulcers or gum irritation?

A: Yes, official product information explicitly lists the treatment of painful conditions like mouth ulcers and sore mouth or gums among its therapeutic indications. The localized anti-inflammatory and pain-relieving action is beneficial for these conditions.

Q: Is Difflam Spray suitable for people with asthma?

A: Official warnings state that caution should be used when this spray is administered to people with a history of bronchial asthma. This is because there is a potential risk of inducing bronchospasm (a sudden narrowing of the airways) in these individuals. Due to the potential risk of bronchospasm, official guidance advises that any patient with a history of asthma should consult a healthcare professional before use.

Q: Why do some people use Difflam Spray before dental procedures?

A: Difflam Spray is indicated for the relief of pain and symptoms associated with conditions like discomfort from dentures or pain experienced after dental surgery. Using it before a procedure can help manage the immediate pain and discomfort that may follow.

Q: How do I clean the nozzle of the Difflam Spray?

A: According to the product information leaflet, after applying the required number of puffs, the end of the spray arm should be wiped with a clean tissue. If the spray mechanism becomes blocked, the patient information leaflet advises against pushing anything into the end and suggests consulting a pharmacist for guidance.

Q: Does Difflam Spray have any effect on my voice or vocal cords?

A: Regulatory documents list a laryngeal spasm as a very rare undesirable effect. A laryngeal spasm is an involuntary contraction of the vocal cords, which can temporarily affect breathing and voice. Laryngeal spasm is a serious, rare side effect, and if it occurs, official guidance recommends consulting a healthcare professional immediately.

Q: Can I use Difflam Spray if I have kidney problems?

A: The product has not been studied in patients with severe renal (kidney) conditions, according to official research limitations. Since the product has not been studied in patients with severe renal conditions, individuals with known kidney issues should consult a healthcare professional before using the spray.

Q: What should I do if I experience a rash after using Difflam Spray?

A: A rash is a documented very rare side effect and may be a sign of a hypersensitivity or allergic reaction. Official guidance states that if signs of allergy occur, the product should be discontinued, and a healthcare professional should be consulted immediately.

Q: Is there a maximum number of days I can continuously use Difflam Spray?

A: Official product instructions recommend that uninterrupted treatment with the spray should not exceed seven days. Using the product for longer than this duration is only advised if under the direct supervision of a medical professional.

Q: Can Difflam Spray interact with herbal supplements?

A: Regulatory documents generally state that no clinically significant interactions are known for the active ingredient, due to its localized application and minimal systemic absorption. Official guidance emphasizes that consulting a healthcare professional about all concurrent products, including herbal supplements, remains a prudent step.

Q: Does Difflam Spray contain any ingredients that can cause drowsiness?

A: Official regulatory documents report no effect on a person's ability to drive or operate machinery. However, symptoms related to the Central Nervous System, such as dizziness and drowsiness, are listed as potential signs of overdose from accidental large ingestion.

Q: Does Difflam Spray expire, and is it still safe to use after the date?

A: Yes, Difflam Spray has a documented shelf life, typically around 3 years from the date of manufacture. Furthermore, official storage instructions state that it must be used within 6 months after the first opening. Official disposal instructions state that expired or unused medicine must be disposed of according to local guidance, often through a pharmacist.

Q: Are there any specific patient groups where caution is advised when using Difflam Spray?

A: Yes, official warnings advise that caution is required for patients with a history of bronchial asthma. Caution is also advised for people who have a known sensitivity or allergy to acetylsalicylic acid (aspirin) or other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).

Q: Does Difflam Spray affect alertness or ability to drive?

A: According to official regulatory documents, there have been no effects reported on alertness or the ability to drive and use machinery. This is consistent with the product's localized action and very low levels of systemic absorption.

How should Difflam Spray be stored and disposed of?

Difflam Spray (benzydamine hydrochloride) must be stored and disposed of according to specific requirements outlined in official regulatory documentation.

Official Storage Conditions

Constraint	Requirement
Temperature	Do not store above 30°C.
Environmental	Do not refrigerate or freeze.
Child Safety	Keep out of the sight and reach of children.
Packaging	Store in the original container and in an upright position.
Stability	Use within 6 months after the first opening.

Disposal Instructions

Official instructions prohibit disposing of this medicine via wastewater or household waste. Any unused or expired Difflam Spray must be disposed of in accordance with local requirements. Patients are instructed to consult a pharmacist for guidance on how to properly discard the product.

Difflam Spray